TYPE 2 DIABETES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In June 2023, Pfizer Inc., a multinational pharmaceutical company, announced that it will continue to advance one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate into clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM). Moving forward, the company will advance the clinical program for danuglipron (PF-06882961) based on the outcomes of the ongoing Phase 2 trial, while discontinuing the clinical development of lotiglipron (PF-07081532).
• In April 2023, Eli Lilly and Company, a pharmaceutical company, announced that tirzepatide (10 mg and 15 mg) resulted in more weight loss than placebo after 72 weeks of treatment in SURMOUNT-2. The study found that tirzepatide outperformed placebo in terms of both co-primary and key secondary objectives. The trial included 938 adult volunteers with obesity or overweight and type 2 diabetes.
• In January 2023, Novo Nordisk, a leading global healthcare company, announced that the U.S. Food and Drug Administration (FDA) issued a label update for Rybelsus (semaglutide) tablets 7 mg or 14 mg, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment. This update removes a previous use restriction stating that the medicine should not be used as the first line of treatment for people with type 2 diabetes.
• In May 2022, Eli Lilly and Company announced that the U.S. FDA has approved Mounjaro (tirzepatide) injection, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 =) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro, the first and only S. FDA-approved GIP and GLP-1 receptor agonist, is a single molecule that activates the body's receptors for GIP and GLP-1, both natural incretin hormones.